PL4010322T3 - Stałe postacie (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaftalen-2-ylo)amino)-n-(1-(2-metylo-1-(neopentyloamino)propan-2-ylo)-1h-imidazol-4-ilo)pentanamidu i ich zastosowanie - Google Patents

Stałe postacie (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaftalen-2-ylo)amino)-n-(1-(2-metylo-1-(neopentyloamino)propan-2-ylo)-1h-imidazol-4-ilo)pentanamidu i ich zastosowanie

Info

Publication number
PL4010322T3
PL4010322T3 PL19758589.6T PL19758589T PL4010322T3 PL 4010322 T3 PL4010322 T3 PL 4010322T3 PL 19758589 T PL19758589 T PL 19758589T PL 4010322 T3 PL4010322 T3 PL 4010322T3
Authority
PL
Poland
Prior art keywords
neopentylamino
pentanamide
tetrahydronaphthalen
propan
imidazol
Prior art date
Application number
PL19758589.6T
Other languages
English (en)
Inventor
Elaine Greer
Stephen Anderson
Mark MALONEY
Shu Yu
Ekaterina Albert
Emily Rigsbee
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority claimed from PCT/US2019/045948 external-priority patent/WO2021029854A1/en
Publication of PL4010322T3 publication Critical patent/PL4010322T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19758589.6T 2019-08-09 2019-08-09 Stałe postacie (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaftalen-2-ylo)amino)-n-(1-(2-metylo-1-(neopentyloamino)propan-2-ylo)-1h-imidazol-4-ilo)pentanamidu i ich zastosowanie PL4010322T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2019/045948 WO2021029854A1 (en) 2019-08-09 2019-08-09 Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
US16/537,394 US10590087B1 (en) 2019-08-09 2019-08-09 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof

Publications (1)

Publication Number Publication Date
PL4010322T3 true PL4010322T3 (pl) 2026-02-16

Family

ID=69778968

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19758589.6T PL4010322T3 (pl) 2019-08-09 2019-08-09 Stałe postacie (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaftalen-2-ylo)amino)-n-(1-(2-metylo-1-(neopentyloamino)propan-2-ylo)-1h-imidazol-4-ilo)pentanamidu i ich zastosowanie

Country Status (13)

Country Link
US (11) US10590087B1 (pl)
JP (1) JP2024149803A (pl)
KR (1) KR20250030524A (pl)
ES (1) ES3055762T3 (pl)
FI (1) FI4010322T3 (pl)
FR (1) FR26C1013I1 (pl)
LT (1) LTPA2026516I1 (pl)
MA (1) MA56748B1 (pl)
MX (1) MX2025004371A (pl)
PL (1) PL4010322T3 (pl)
SI (1) SI4010322T1 (pl)
TW (1) TWI867022B (pl)
ZA (1) ZA202202325B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4010322T3 (pl) * 2019-08-09 2026-02-16 Pfizer Inc. Stałe postacie (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaftalen-2-ylo)amino)-n-(1-(2-metylo-1-(neopentyloamino)propan-2-ylo)-1h-imidazol-4-ilo)pentanamidu i ich zastosowanie
US20230049311A1 (en) * 2019-08-09 2023-02-16 Springworks Therapeutics, Inc. Methods of treating desmoid tumors with (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide
US11884634B2 (en) * 2019-08-09 2024-01-30 Pfizer Inc. Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
AU2021244215A1 (en) 2020-03-26 2022-10-13 Seagen Inc. Methods of treating multiple myeloma
IL300405A (en) 2020-08-20 2023-04-01 Univ Leland Stanford Junior Methods for treating respiratory diseases characterized by excessive secretion of mucus
TWI905452B (zh) 2021-09-01 2025-11-21 美商斯普林渥克斯治療有限公司 尼羅司他（ｎｉｒｏｇａｃｅｓｔａｔ）之合成
US11504354B1 (en) 2021-09-08 2022-11-22 SpringWorks Therapeutics Inc.. Chlorinated tetralin compounds and pharmaceutical compositions
WO2023081830A2 (en) * 2021-11-05 2023-05-11 Springworks Therapeutics, Inc. Compositions and treatments with nirogacestat
WO2023150559A2 (en) * 2022-02-01 2023-08-10 Springworks Therapeutics, Inc. Treatment of ovarian cancer with nirogacestat
WO2023174390A1 (zh) * 2022-03-17 2023-09-21 苏州科睿思制药有限公司 尼罗司他二氢溴酸盐的晶型及其制备方法和用途
US12036207B2 (en) 2022-05-20 2024-07-16 Springworks Therapeutics, Inc. Treatments with nirogacestat
US12138246B2 (en) 2022-05-20 2024-11-12 Springworks Therapeutics, Inc. Treatments with nirogacestat
US11951096B2 (en) 2022-05-20 2024-04-09 Springworks Therapeutics, Inc. Treatments with nirogacestat
CN119486713A (zh) * 2022-05-20 2025-02-18 斯普林渥克斯治疗有限公司 尼罗加司他治疗
EP4678635A1 (en) * 2023-03-09 2026-01-14 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of nirogacestat dihydrobromate, and preparation method therefor and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5160260A1 (es) 1999-02-19 2002-05-30 Lilly Co Eli Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
ATE399155T1 (de) 2004-03-23 2008-07-15 Pfizer Prod Inc Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
US10211310B2 (en) 2012-06-12 2019-02-19 Novellus Systems, Inc. Remote plasma based deposition of SiOC class of films
WO2015092614A1 (en) 2013-12-20 2015-06-25 Pfizer Inc. Activating notch alterations in breast cancer
KR20180030545A (ko) * 2015-06-22 2018-03-23 다이닛본 스미토모 세이야꾸 가부시끼가이샤 바이사이클릭 헤테로사이클릭 아미드 유도체
WO2018045273A2 (en) 2016-09-02 2018-03-08 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
WO2019053727A1 (en) 2017-09-18 2019-03-21 Ramot At Tel-Aviv University Ltd. REDIFFERENCING IN VITRO DEVELOPED CELLS FROM HUMAN PANCREATIC ISLAND BEA CELLS ADULPTED BY SMALL MOLECULE INHIBITORS OF THE SIGNALING PATH
WO2020131998A1 (en) * 2018-12-18 2020-06-25 The University Of North Carolina At Chapel Hill Notch inhibitors for the treatment of vascular malformations
PL4010322T3 (pl) 2019-08-09 2026-02-16 Pfizer Inc. Stałe postacie (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaftalen-2-ylo)amino)-n-(1-(2-metylo-1-(neopentyloamino)propan-2-ylo)-1h-imidazol-4-ilo)pentanamidu i ich zastosowanie
US20230049311A1 (en) 2019-08-09 2023-02-16 Springworks Therapeutics, Inc. Methods of treating desmoid tumors with (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide

Also Published As

Publication number Publication date
US11820748B2 (en) 2023-11-21
US10590087B1 (en) 2020-03-17
US10710966B1 (en) 2020-07-14
JP2024149803A (ja) 2024-10-18
MA56748B1 (fr) 2025-12-31
US12116347B2 (en) 2024-10-15
US11905255B1 (en) 2024-02-20
US20230167069A1 (en) 2023-06-01
LTPA2026516I1 (pl) 2026-05-11
US20230406827A1 (en) 2023-12-21
US20210269407A1 (en) 2021-09-02
TWI867022B (zh) 2024-12-21
US11845732B2 (en) 2023-12-19
US11884635B2 (en) 2024-01-30
TW202525782A (zh) 2025-07-01
TW202120482A (zh) 2021-06-01
US20210040045A1 (en) 2021-02-11
ZA202202325B (en) 2024-06-26
KR20250030524A (ko) 2025-03-05
MX2025004371A (es) 2025-05-02
US20260078096A1 (en) 2026-03-19
US11566006B2 (en) 2023-01-31
US20240051924A1 (en) 2024-02-15
ES3055762T3 (en) 2026-02-16
US20230382872A1 (en) 2023-11-30
SI4010322T1 (sl) 2026-02-27
FI4010322T3 (fi) 2025-12-16
US12297177B2 (en) 2025-05-13
US20230202987A1 (en) 2023-06-29
FR26C1013I1 (fr) 2026-04-24
US10941118B2 (en) 2021-03-09
US20240150299A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
SI4010322T1 (sl) Trdne oblike (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol- 4-il)pentanamida in njegova uporaba
HRP20251641T1 (hr) Oblici čvrstog stanja (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida i njihova uporaba
MA55136A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA54261A (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
MA55301A (fr) Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation
MA56191A (fr) Inhibiteurs de l'autophagie à base d'amide d'aminopyrimidine et leurs procédés d'utilisation
ZA202211870B (en) Imidazolidinone derivatives and medical use thereof
EP3975703A4 (en) PENETRATING TOPICAL PAIN RELIEF COMPOSITIONS AND METHOD OF USE
PL374700A1 (pl) Zastosowanie inhibitorów syntezy cytokiny do leczenia zespołu suchego oka
EP3843720A4 (en) COMPOSITIONS OF CXCR4 INHIBITORS AND METHODS OF MANUFACTURE AND USE
IL286248A (en) Tyk2 inhibitors and uses thereof
MA41496A (fr) Compositions pharmaceutiques comprenant la n-(3,5-diméthoxyphényl)-n'-(1-méthyléthyl)-n-[3-(1-méthyl-1h-pyrazol-4-yl)quinoxalin-6-yl]éthane-1,2-diamine
EP3740186A4 (en) HYGIENE PRODUCT CONTAINER AND METHODS OF USE
EP3735242A4 (en) METALLO-BETA-LACTAMASE INHIBITORS AND METHOD OF USING THEREOF
CO2024002573A2 (es) Síntesis de nirogacestat
EP3947351A4 (en) SMALL MOLECULAR PARG INHIBITORS AND METHODS OF USE
EP3996704A4 (en) MULTIPLE THERAPY INCLUDING GPR119 AGONISTS AND DPP-4 INHIBITORS
IL310209A (en) ROCK2 inhibitors and their uses
EA202091082A1 (ru) Композиция и способ лечения периферической т-клеточной лимфомы и кожной т-клеточной лимфомы
PL4161929T3 (pl) 1-(5-(2-cyjanopirydyn-4-ylo)oksazolo-2-karbonylo)-4-metyloheksahydropirolo[3,4-b]pirolo-5(1h)-karbonitryl jako inhibitor usp30 do zastosowania w leczeniu dysfunkcji mitochondriów, nowotworu i zwłóknienia
EP3801471A4 (en) INHIBITORS OF GLYCOSPHINGOLIPID SYNTHESIS AND METHODS OF USE
IL313081A (en) New HDAC inhibitors and their medical use
IL311733A (en) Hydrochloride salt of inupdanant, pharmaceutical preparations and methods of using it
EP3752517A4 (en) CYCLINE DEPENDENT KINASE DEGRADERS AND METHOD OF USING
EP4054549A4 (en) Topical formulations of cyclooxygenase inhibitors and their use